A cohort study in three Scandinavian countries found no significant increase in thyroid cancer risk with glucagon-like peptide 1 receptor agonists.
TOPLINE: No significant association was found between the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and thyroid cancer over nearly 4 years. METHODOLOGY: A cohort study using data from nationwide registers in Denmark, Norway, and Sweden between 2007 and 2021 included 145,410 patients who initiated GLP-1 RAs and 291,667 propensity score-matched patients initiating dipeptidyl peptidase 4 (DPP4) inhibitors as active comparators. Additional analysis included 111,744 who initiated GLP-1 RAs and 148,179 patients initiating sodium-glucose cotransporter 2 (SGLT2) inhibitors. Overall, mean follow-up time was 3.9 years, with 25% followed for more than 6 years. TAKEAWAY: The most common individual GLP-1 RAs were liraglutide (57.3%) and semaglutide (32.9%). During follow-up, there were…